Acute and long-term results of bipolar radiofrequency catheter ablation of refractory ventricular arrhythmias of deep intramural origin.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
09 2020
Historique:
received: 30 09 2019
revised: 23 03 2020
accepted: 01 04 2020
pubmed: 1 5 2020
medline: 7 9 2021
entrez: 1 5 2020
Statut: ppublish

Résumé

Successful bipolar radiofrequency catheter ablation (RFCA) of refractory ventricular arrhythmias (VAs) has been reported. However, the efficacy, safety, and long-term outcomes of bipolar RFCA of VAs are not fully determined. The purpose of this study was to evaluate the effectiveness and safety of bipolar RFCA in treating refractory VAs during long-term follow-up. Eighteen patients who underwent bipolar RFCA for ventricular tachycardia (VT) at 7 institutions were retrospectively investigated. Underlying heart diseases included remote myocardial infarction (n = 3 [17%]) and nonischemic cardiomyopathy (n = 15 [83%]). Although unipolar RFCA was performed in all patients, either it failed to suppress VT or VT recurred. The interventricular septum, left ventricular free wall, and left ventricular summit were targeted for bipolar RFCA. Acute success (VT termination and/or noninducibility) was achieved with bipolar RFCA in 16 patients (89%). Complications during the procedure included complete atrioventricular block (n = 2) and coronary artery stenosis (n = 1). One patient underwent chemical ablation after bipolar RFCA failure. At 12-month follow-up, VT reoccurred in 8 patients (44%). However, in patients with recurrence, VT burden had decreased: only 4 patients underwent re-RFCA, and only 1 of the 4 required chemical ablation. In the remaining 4 patients, re-RFCA was not required, as VT was controlled by medication or an implantable cardioverter-defibrillator. Bipolar RFCA is useful for acute suppression of refractory VT. Although VT recurrence rates during long-term follow-up were relatively high, we observed a significant reduction in VT burden.

Sections du résumé

BACKGROUND
Successful bipolar radiofrequency catheter ablation (RFCA) of refractory ventricular arrhythmias (VAs) has been reported. However, the efficacy, safety, and long-term outcomes of bipolar RFCA of VAs are not fully determined.
OBJECTIVE
The purpose of this study was to evaluate the effectiveness and safety of bipolar RFCA in treating refractory VAs during long-term follow-up.
METHODS
Eighteen patients who underwent bipolar RFCA for ventricular tachycardia (VT) at 7 institutions were retrospectively investigated. Underlying heart diseases included remote myocardial infarction (n = 3 [17%]) and nonischemic cardiomyopathy (n = 15 [83%]). Although unipolar RFCA was performed in all patients, either it failed to suppress VT or VT recurred. The interventricular septum, left ventricular free wall, and left ventricular summit were targeted for bipolar RFCA.
RESULTS
Acute success (VT termination and/or noninducibility) was achieved with bipolar RFCA in 16 patients (89%). Complications during the procedure included complete atrioventricular block (n = 2) and coronary artery stenosis (n = 1). One patient underwent chemical ablation after bipolar RFCA failure. At 12-month follow-up, VT reoccurred in 8 patients (44%). However, in patients with recurrence, VT burden had decreased: only 4 patients underwent re-RFCA, and only 1 of the 4 required chemical ablation. In the remaining 4 patients, re-RFCA was not required, as VT was controlled by medication or an implantable cardioverter-defibrillator.
CONCLUSION
Bipolar RFCA is useful for acute suppression of refractory VT. Although VT recurrence rates during long-term follow-up were relatively high, we observed a significant reduction in VT burden.

Identifiants

pubmed: 32353585
pii: S1547-5271(20)30348-9
doi: 10.1016/j.hrthm.2020.04.028
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1500-1507

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Miyako Igarashi (M)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Akihiko Nogami (A)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. Electronic address: anogami@md.tsukuba.ac.jp.

Seiji Fukamizu (S)

Department of Cardiology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.

Yukio Sekiguchi (Y)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Junichi Nitta (J)

Department of Cardiology, Saitama Red Cross Hospital, Saitama, Japan.

Naka Sakamoto (N)

Department of Cardiology, Asahikawa Medical University, Hokkaido, Japan.

Yuichiro Sakamoto (Y)

Department of Cardiology, Toyohashi Heart Center, Aichi, Japan.

Kenji Kurosaki (K)

Department of Heart Rhythm Management, Yokohama Rosai Hospital, Kanagawa, Japan.

Yoshihide Takahashi (Y)

Department of Cardiovascular Medicine, Disaster Medical Center, Tokyo, Japan.

Akira Kimata (A)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Yuki Komatsu (Y)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Takeshi Machino (T)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Kenji Kuroki (K)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Hiro Yamasaki (H)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Kazutaka Aonuma (K)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Masaki Ieda (M)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH